Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002123 · ClinicalTrials.gov registry record · Phase 3
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
A Phase 3 study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002123: Completed Phase 3 study, sponsored by Pharmacia and Upjohn.
NCT00002123 is a Phase 3 study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002123, a Phase 3 study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
Interventions
- DRUG Didanosine
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002123 record still lists
NCT00002123 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which Didanosine is the first listed.
NCT00002123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002123 about?
NCT00002123 is a clinical study titled "A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3". To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.
What is the current status of trial NCT00002123?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002123?
The interventions under investigation include: Didanosine (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002123?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.